Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion

Expert Opinion on Drug Delivery
Wim CeelenKatrien Remaut

Abstract

Introduction: The rationale for intraperitoneal (IP) drug delivery for patients with peritoneal metastases (PM) is based on the pharmacokinetic advantage resulting from the peritoneal-plasma barrier, and on the potential to adequately treat small, poorly vascularized PM. Despite a history of more than three decades, many aspects of IP drug delivery remain poorly studied.Areas covered: We outline the anatomy and physiology of the peritoneal cavity, including the pharmacokinetics of IP drug delivery. We discuss transport mechanisms governing tissue penetration of IP chemotherapy, and how these are affected by the biomechanical properties of the tumor stroma. We provide an overview of the current clinical evidence on IP chemotherapy in ovarian, colorectal, and gastric cancer. We discuss the current limitations of IP drug delivery and propose several potential areas of progress.Expert opinion: The potential of IP drug delivery is hampered by off-label use of drugs developed for systemic therapy. The efficacy of IP chemotherapy for PM depends on cancer type, disease extent, and mode of drug delivery. Results from ongoing randomized trials will allow to better delineate the potential of IP chemotherapy. Promising approaches include I...Continue Reading

References

Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G LosJ G McVie
Apr 1, 1997·European Journal of Morphology·K N Michailova
Jan 27, 1998·Cancer Chemotherapy and Pharmacology·P JacquetP H Sugarbaker
Jan 6, 2000·Annals of Surgical Oncology·P H Sugarbaker, D Chang
Feb 27, 2001·Journal of Surgical Oncology·S R PestieauP H Sugarbaker
Jul 6, 2002·Critical Reviews in Oncology/hematology·Bert HildebrandtHanno Riess
Mar 12, 2003·Annals of Biomedical Engineering·C Pozrikidis, D A Farrow
May 22, 2003·Cancer Chemotherapy and Pharmacology·Vinicius de Lima VazquezPaul H Sugarbaker
Jul 8, 2003·The Journal of Pathology·Olivier De Wever, Marc Mareel
Apr 24, 1958·Annals of the New York Academy of Sciences·S G ECONOMOUW H COLE
Oct 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vic J VerwaalFrans A N Zoetmulder
Apr 20, 2005·Annals of Anatomy = Anatomischer Anzeiger : Official Organ of the Anatomische Gesellschaft·Krassimira N MichailovaWolfgang Kühnel
Sep 20, 2005·Cancer Cell·Matthew J PaszekValerie M Weaver
Jan 6, 2006·The New England Journal of Medicine·Deborah K ArmstrongUNKNOWN Gynecologic Oncology Group
Jan 21, 2006·Journal of Biomedical Materials Research. Part a·Daniel S KohaneRobert Langer
Nov 30, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T D YanP H Sugarbaker
Dec 22, 2006·Cancer Treatment Reviews·R M SmeenkF A N Zoetmulder
Jan 18, 2007·Journal of Cellular Biochemistry·Hanchen LiJeanmarie Houghton
May 15, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L BijelicP H Sugarbaker
Nov 29, 2007·Anti-cancer Drugs·Mark N KirsteinTodd M Tuttle
May 2, 2008·The Oncologist·Ignace VergotePatrick Berteloot
Jan 24, 2009·Nature Reviews. Cancer·Darci T ButcherValerie M Weaver
Jul 8, 2009·Biophysical Journal·Vikash P ChauhanRakesh K Jain
Jul 28, 2009·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·T C ChuaD L Morris
Sep 29, 2009·Lancet·Peter McCullochJan Vandenbroucke
Feb 27, 2010·The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology·Zi-Bin WangJi-Cheng Li
Oct 6, 2011·Archives of Pathology & Laboratory Medicine·Nicole C Panarelli, Rhonda K Yantiss
Nov 1, 2011·Nature Medicine·Kristin M NiemanErnst Lengyel
Jun 6, 2013·Cancer Research·Diane GoéréLaurence Zitvogel
Jun 27, 2013·Integrative Biology : Quantitative Biosciences From Nano to Macro·Edmond W K Young

❮ Previous
Next ❯

Citations

Jun 18, 2020·Advanced Healthcare Materials·Leen Van de SandeWim Ceelen
Nov 3, 2020·Advanced Drug Delivery Reviews·Mohammad Rahimi-GorjiWim Ceelen
Jul 25, 2021·Cancers·Roxan F C P A HeldermanJohannes Crezee
Oct 12, 2021·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Helena BraetKatrien Remaut

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.